Post Traumatic Stress Disorder Phase II Clinical Trial

Current pharmacotherapies have fallen short, or in many cases fail to offer consistent relief. Extensive research has indicated the potential for CBD to alleviate PTSD symptoms, particularly in conjunction with neurocognitive impairment. CBD’s potential impact on anxiety reduction and fear extinction, coupled with its observed ability to enhance memory and protect vital brain circuitry, make it a promising candidate for those suffering from PTSD, and PTSD with TBI.

With this in mind, Ananda Scientific, in collaboration with investigators from NYU Gross School of Medicine is undertaking a groundbreaking endeavor to address this critical gap.

A Phase II clinical trial is currently in process with Esther Blessings MD, PhD, as principal investigator. This trial, encompassing 120 subjects, is evaluating Nantheia™ A1002N5S, Ananda’s investigational CBD drug utilizing it proprietary Liquid Structure ™ delivery technology, as a potential a PTSD treatment. The outcome of this trial will be its ability to reduce a patient’s CAPS-5 score (a validated measure of person’s PTSD symptoms) and in enhancing neurocognitive function.

For more details, refer to the clinicaltrials.gov link (https://clinicaltrials.gov/study/NCT04550377) and press releases issued over the course of the study:

1. [ANANDA Scientific and NYU Grossman School of Medicine Announce Clinical Trial Utilizing Liquid Structure™ Cannabidiol (CBD) for Treatment of Post-Traumatic Stress Disorder (PTSD)](https://www.businesswire.com/news/home/20210112005378/en)

2. [ANANDA Scientific and NYU Grossman School of Medicine Announce First Patient Enrolled in the Clinical Trial Evaluating Liquid Structure™ Cannabidiol (CBD) for Treatment of Post-Traumatic Stress Disorder (PTSD)](https://www.businesswire.com/news/home/20210608005132/en)